The rising prevalence of psoriasis, affecting more than 7.5 million Americans, is fueling exponential growth in the dermatology drug market with projections indicating an increase from $40.55 billion in 2023 to over $70 billion by 2030. The high cost of psoriasis treatments, often exceeding $160,000 per patient annually for specialty drugs like Stelara and Tremfya, create significant challenges for employers managing self-funded benefit plans.
The trend can be compared to the massive rise of GLP-1s, another class of drugs with steep price tags and increasing demand that is having significant financial implications for employers. In the case of psoriasis drugs, biosimilars such as alternatives to Humira offer hope for reducing costs.
To manage the growing financial burden of psoriasis treatment, employers can learn from the impact of GLP-1s when considering strategies that strike a balance between affordability and access. Read this HR Executive article from RxBenefits’ Chief Pharmacy Officer, Mark Campbell, to learn more.
